Panel Overview

G2M offers a panel for liquid biopsy covering major cancer types like Lung, Breast and Colorectal cancer. This panel gives a detailed insight on cancer-related genes to uncover known as well as novel variants for further investigation.

Key features & highlights:

• Focused Comprehensively Validated Panel:Covers all relevant genes with the ability to detect ultra-low VAF mutations, delivering clinical-grade precision you can trust.
• Low Input: Process compatible with low input quality compromised samples.
• Robust and Rapid Workflow: Hybridization enhancer technology and enzyme-based library preparation enables quick turnaround time.
• Hassle-Free Data and Reporting: User-friendly software for data upload, automated and cloud-based analysis followed by report generation.

ctDNA Breast Cancer

Breast Cancer Detection and Monitoring Powered by Liquid Biopsy and NGS Breast cancer is characterized by the uncontrolled proliferation of malignant epithelial cells within the breast tissue, leading to tumor formation. Although rare in men, it remains predominantly a disease of women and represents a major global health burden. Breast cancer is represented by substantial heterogeneity, encompassing diverse genetic alterations and distinct histopathological subtypes. Despite advances in research, the precise molecular mechanisms driving its initiation and progression remain incompletely understood. The biggest risk factors include simply being female and increasing age. Other factors like family history, gene mutations, race/ethnicity, pregnancy history, breast feeding history and unhealthy lifestyle can also raise the likelihood of developing breast cancer. Research shows that inherited genetic factors contribute to about 5-10% of all breast cancer cases and follow an autosomal dominant inheritance pattern, but in women under 30, they may explain up to 25% of diagnoses. Among these, mutations in the BRCA1 and BRCA2 genes are the most well-recognized causes of hereditary breast cancer risk.

How Genes Affect Breast Cancer:

Hereditary breast cancer risk is largely determined by the specific gene affected. Pathogenic variants in BRCA1 and BRCA2 are transmitted in an autosomal dominant manner, whereby a single mutant allele is sufficient to confer increased susceptibility. Although breast cancer predominantly affects women, these germline mutations can be inherited from either the maternal or paternal lineage.

In breast cancer, cell-free circulating tumor DNA (ctDNA) is emerging as a powerful, noninvasive biomarker that may reduce the need for traditional tissue biopsies. Through liquid biopsy, ctDNA shed by tumors into the bloodstream can be analyzed to track genetic changes. Using next-generation sequencing (NGS), even very small amounts of ctDNA can be detected with high accuracy, enabling the identification of both specific gene mutations and broader, genome-wide alterations that drive breast cancer. This helps in guiding targeted therapies and personalized treatment choices. The ctDNA Breast Cancer Panel analyzes key genes linked to tumor growth and treatment response. This table highlights important genes along with the targeted therapies that may be considered.